Targeting acetylcholinesterase to treat neurodegeneration
The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Neurodegenerative disorders, such as Alzheimer's disease, are often characterised by the degeneration of the cholinergic system. Thus, the aim of many treatment regimens is to support this system either by means of muscarinic agonists or by inhibitors of acetylcholinesterase (AChE), the latter being able to increase the concentration of acetylcholine. However, both pharmacological groups of drugs can only help in the beginning of the progressive disease. The finding that the occupation of the peripheral anionic site of AChE is able to stop the formation of the amyloid plaque led to the development of bivalent ligands that occupy both the active and the peripheral site. This dual action might be more beneficial for treatment of Alzheimer s disease than simple inhibition of the acetylcholine hydrolysis. Thus, the new bivalent ligands are the focus of this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., & Silman, I. (1991) · Science · doi:10.1126/science.1678899 · Cited by 2,707 · cited 2×
“The indole ring is finally stacked onto the aromatic ring of Trp279 and the NH group of the indole ring interacts with the hydroxyl oxygen of Tyr70 [76].”
BackgroundQuaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.
Harel, M., Schalk, I., Ehret-Sabatier, L., Bouet, F., Goeldner, M., Hirth, C., Axelsen, P. H., Silman, I., & Sussman, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.19.9031 · Cited by 899 · cited 1×
“Examination of X-ray crystal structure of tacrine (Figure 3) [33] revealed the 4-aminoquinoline portion of tacrine molecule to be responsible for the binding of the drug to the enzyme, whereas the cyclohexyl ring acted mostly as a block for the substrate at the active site [34].”
BackgroundKryger, G., Silman, I., & Sussman, J. L. (1999) · Structure · doi:10.1016/s0969-2126(99)80040-9 · Cited by 757
Alpha Beta-Hydrolase Fold Enzymes Structures, Functions and Mechanisms
Holmquist, M. (2000) · Current Protein and Peptide Science · doi:10.2174/1389203003381405 · Cited by 646 · cited 1×
“It is known for its high turnover; the hydrolysis of the substrate ACh occurs with ∼ 103-fold and 1013-fold greater activity than the spontaneous hydrolysis of ACh by serine proteases and the related BuChE, respectively [25].”
Backgroundβ-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies
Bartolini, M., Bertucci, C., Cavrini, V., & Andrisano, V. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01514-9 · Cited by 568 · cited 3×
“It is well known that propidium is one of the most selective ligands for the PAS of the AChE [80] and it has been the most potent inhibitor of AChE-induced Aβ aggregation for a long time [5,81].”
BackgroundMethodCholinesterase inhibitors: new roles and therapeutic alternatives
GIACOBINI, E. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.11.017 · Cited by 555 · cited 1×
“As AD progresses, ACh regulation may become increasingly depend on BuChE [61,62].”
BackgroundButyrylcholinesterase: An Important New Target in Alzheimer’s Disease Therapy
Greig, N. H., Lahiri, D. K., & Kumar, S. (2002) · International Psychogeriatrics · doi:10.1017/s1041610203008676 · Cited by 467 · cited 1×
“As AD progresses, ACh regulation may become increasingly depend on BuChE [61,62].”
BackgroundGalantamine: A Review of its Use in Alzheimer??s Disease
Scott, L. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200060050-00008 · Cited by 383
Bohnen, N. I., Kaufer, D. I., Hendrickson, R., Ivanco, L. S., Lopresti, B. J., Constantine, G. M., Mathis, C. A., Davis, J. G., Moore, R. Y., & DeKosky, S. T. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0971-0 · Cited by 364 · cited 1×
“Therefore, despite the beneficial effect on the cognitive state of PD patients, any patient administered a cholinesterase inhibitor should be kept under surveillance in order to control the response and adverse effects [12].”
BackgroundCurrent Pharmacotherapy for Alzheimer's Disease
Lleó, A., Greenberg, S. M., & Growdon, J. H. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131442 · Cited by 345
Cited by
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Nachon, F., Carletti, E., Ronco, C., Trovaslet, M., Nicolet, Y., Jean, L., & Renard, P.-Y. (2013) · Biochemical Journal · doi:10.1042/bj20130013 · Cited by 478
Cellular and molecular actions of Methylene Blue in the nervous system
Oz, M., Lorke, D. E., Hasan, M., & Petroianu, G. A. (2011) · Medicinal Research Reviews · doi:10.1002/med.20177 · Cited by 443
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Structure-Based Search for New Inhibitors of Cholinesterases
Bajda, M., Więckowska, A., Hebda, M., Guzior, N., Sotriffer, C., & Malawska, B. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14035608 · Cited by 274
Fernández-Bachiller, M. I., Pérez, C., González-Muñoz, G. C., Conde, S., López, M. G., Villarroya, M., García, A. G., & Rodríguez-Franco, M. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100329q · Cited by 268
Fernández-Bachiller, M. I., Pérez, C., Monjas, L., Rademann, J., & Rodríguez-Franco, M. I. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201460y · Cited by 268
Bolognesi, M. L., Cavalli, A., Valgimigli, L., Bartolini, M., Rosini, M., Andrisano, V., Recanatini, M., & Melchiorre, C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701225u · Cited by 260
Methylene blue and Alzheimer's disease
Oz, M., Lorke, D. E., & Petroianu, G. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.034 · Cited by 257
Metadata
- Authors
- Holzgrabe, U., Kapková, P., Alptüzün, V., Scheiber, J., & Kugelmann, E.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2007-01-17
- Volume
- 11
- Issue
- 2
- Pages
- 161-179
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2107857520
- Cited by
- 217
- References
- 94
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.